ImmunoPrecise Antibodies (NASDAQ:IPA) Releases Quarterly Earnings Results, Meets Expectations

ImmunoPrecise Antibodies (NASDAQ:IPA) posted its quarterly earnings data on Friday. The company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06), Zacks reports. ImmunoPrecise Antibodies had a negative return on equity of 73.74% and a negative net margin of 114.50%.

ImmunoPrecise Antibodies Trading Down 6.9 %

Shares of IPA stock traded down $0.03 during mid-day trading on Friday, hitting $0.41. The company’s stock had a trading volume of 178,395 shares, compared to its average volume of 7,933,911. ImmunoPrecise Antibodies has a 52 week low of $0.27 and a 52 week high of $1.59. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.85 and a current ratio of 1.01. The company’s fifty day simple moving average is $0.44 and its 200-day simple moving average is $0.48. The company has a market cap of $12.74 million, a PE ratio of -0.53 and a beta of 0.09.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of ImmunoPrecise Antibodies in a research report on Friday, March 14th.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.